AI in healthcare is growing, but clinicians still lead

Artificial intelligence is gaining ground across healthcare, and the latest literature keeps landing on the same conclusion: it can be powerful, but it isn’t ready to replace clinicians. A recent narrative review of healthcare AI described strong results in imaging, lab medicine, rehabilitation, and conversational systems, especially in controlled environments, while stressing persistent concerns around bias, ethical use, generalizability, and oversight. In veterinary medicine, that same tension is becoming more visible as AI shifts from a future-facing concept to a workflow tool already being marketed to clinics. (pmc.ncbi.nlm.nih.gov)

That matters because veterinary teams are approaching AI from two directions at once. On one side is the research literature, which shows growing interest in AI for companion animal diagnostics, health monitoring, behavior assessment, and welfare. A recent review of AI in companion animal care found momentum across those categories, but concluded that applications beyond diagnostics remain fragmented and insufficiently integrated into routine care. On the other side are software vendors building products for immediate operational use, including dictation, intake, triage, record summaries, risk flagging, and invoicing support. Digitail, for example, now markets more than 20 AI-enabled workflows for veterinary teams. (pubmed.ncbi.nlm.nih.gov)

The gap between promise and proof is the central issue. In human healthcare, systematic reviews suggest AI scribes and related tools can improve efficiency and reduce documentation burden, but still require manual correction and stronger implementation evidence. Broader healthcare research also continues to show that many AI systems perform best in retrospective datasets or tightly controlled settings, with less certainty once they encounter messy, real-world workflows, shifting case mix, and uneven data quality. That’s especially relevant for veterinary medicine, where species differences, variable record quality, and lower volumes of labeled data can make external validation harder. The implication here is an inference from the human and veterinary evidence bases taken together, rather than a direct finding from one paper. (pubmed.ncbi.nlm.nih.gov)

Regulators are increasingly focused on that exact problem. The FDA’s recent draft guidance for AI-enabled medical devices lays out lifecycle expectations for design, development, maintenance, and documentation, with explicit attention to transparency and bias. FDA materials on machine learning-enabled devices also emphasize explainability, clear user information, and the performance of the human-AI team, not just the algorithm in isolation. Although those frameworks are written for human medical products, they offer a useful template for veterinary technology companies and clinic leaders evaluating AI claims. (fda.gov)

Professional guidance is moving in a similar direction. The AVMA’s policy on technology use in veterinary medicine supports responsible, ethical development and use of technology that advances animal health and welfare. That’s broad, but it aligns with the growing consensus that AI should augment veterinary work rather than displace it. Public and stakeholder research in healthcare points the same way: people are generally more comfortable with AI that expands access to information or supports clinical work than with AI acting autonomously or replacing clinician interaction. (avma.org)

Why it matters: For veterinary professionals, the near-term value of AI is likely to be operational first and clinical second. Tools that reduce note-writing, summarize records, surface missing information, and help standardize follow-up may offer the fastest return, especially in practices dealing with staffing strain and documentation overload. But clinics will need to ask harder questions before relying on any product for diagnostic or decision support: Was it validated externally? In what species and settings? How are errors surfaced? Who remains accountable when the tool is wrong? Those questions aren’t barriers to adoption, they’re the conditions for safe adoption. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase will likely bring more veterinary-specific AI tools, more claims about clinical support, and more pressure for evidence that those systems work outside pilot environments. Watch for peer-reviewed validation studies, clearer product labeling around intended use and limitations, and, eventually, more defined expectations from veterinary professional bodies and regulators about oversight, transparency, and accountability. (fda.gov)